Karolina Sulek
Karolina Sulek has a PhD in metabolomics of gut microbiota and the host cross-communication. She is currently working at Novo Nordisk as a Scientific Director, leading the translational side of omics with particular interest in metabolomics in cardiometabolic disease understanding, discovery of new medicine and understanding of GLP1RA mode of action. Karolina has 15 years of experience in clinical metabolomics and lipidomics within metabolic diseases, diabetes, obesity and related complications. She joined Novo Nordisk from Steno Diabetes Center Copenhagen (SDCC), where she was leading Translational Medicine team, focusing on diabetes complication prediction and biomarker application for the benefit of patients at SDCC. Her team’s research was directed towards clinically applicable omics technology development, making omics more approachable for clinical purposes. Karolina is also a co-founder and currently a member of Clinical Metabolomics Network (CLIME.DK), which is a scientific base for all researchers and clinicians interested in clinical metabolomics in Europe. Her aim is to elevate metabolomics into strong clinical and medicinal translation.